Applicable advances in the molecular pathology of glioblastoma (Q38528700)

3 September 2017

1 reference

title

Applicable advances in the molecular pathology of glioblastoma (English)

1 reference

3 September 2017

Toshihiko Wakabayashi

series ordinal

4

object named as

Toshihiko Wakabayashi

1 reference

3 September 2017

5

Atsushi Natsume

1 reference

3 September 2017

2

Kazuya Motomura

1 reference

3 September 2017

Melissa Ranjit

1

1 reference

PubMed ID

26078107

3 September 2017

Fumiharu Ohka

series ordinal

3

1 reference

3 September 2017

16 June 2015

1 reference

3 September 2017

Brain Tumor Pathology

1 reference

3 September 2017

32

1 reference

3 September 2017

3

1 reference

3 September 2017

153-162

1 reference

https://scigraph.springernature.com/pub.10.1007/s10014-015-0224-6

3 September 2017

0 references

cites work

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

A developmental taxonomy of glioblastoma defined and maintained by MicroRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Transcriptional control of oligodendrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Human oligodendrocytes from embryonic stem cells: conserved SHH signaling networks and divergent FGF effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

The oligodendrocyte precursor cell in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Efficient serum-free derivation of oligodendrocyte precursors from neural stem cell-enriched cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Shedding light on proteolytic cleavage of CD44: the responsible sheddase and functional significance of shedding

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Podoplanin associates with CD44 to promote directional cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

A simplified approach for the molecular classification of glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Subtyping of gliomas of various WHO grades by the application of immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Subclassification of newly diagnosed glioblastomas through an immunohistochemical approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

21 January 2018

Surfing the p53 network

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Molecular classification of low-grade diffuse gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Olig2 labeling index is correlated with histological and molecular classifications in low-grade diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Genetic pathways to primary and secondary glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Constitutive EGFR signaling in oligodendrocyte progenitors leads to diffuse hyperplasia in postnatal white matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Localization of epidermal growth factor receptors and putative neuroblasts in human subependymal zone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

EGFRvIII-targeted vaccination therapy of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Comparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

MGMT testing--the challenges for biomarker-based glioma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Advances in genetic and epigenetic analyses of gliomas: a neuropathological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

ATRX dysfunction induces replication defects in primary mouse cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Role of telomeres and telomerase in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

The somatic genomic landscape of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Promoting a new brain tumor mutation: TERT promoter mutations in CNS tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Histone variants--ancient wrap artists of the epigenome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

H3F3A K27M mutations in thalamic gliomas from young adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Identification of a novel family of oligodendrocyte lineage-specific basic helix-loop-helix transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Signal transduction by the platelet-derived growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Early contribution of pericytes to angiogenic sprouting and tube formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Recent insights into PDGF-induced gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Controversies over the diagnosis of oligodendroglioma: a report from the satellite workshop at the 4th international symposium of brain tumor pathology, Nagoya Congress Center, May 23, 2012.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

Characteristics of glioma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10014-015-0224-6

10.1007/S10014-015-0224-6

21 January 2018

Identifiers

DOI

1 reference

3 September 2017

1 reference

PubMed ID

26078107